Original Article | Published:

Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease: a meta-analysis study (N=7277)

Molecular Psychiatry volume 22, pages 312320 (2017) | Download Citation

Abstract

Studies suggest that dysfunction of brain-derived neurotrophic factor (BDNF) is a possible contributor to the pathology and symptoms of Alzheimer’s disease (AD). Several studies report reduced peripheral blood levels of BDNF in AD, but findings are inconsistent. This study sought to quantitatively summarize the clinical BDNF data in patients with AD and mild cognitive impairment (MCI, a prodromal stage of AD) with a meta-analytical technique. A systematic search of Pubmed, PsycINFO and the Cochrane Library identified 29 articles for inclusion in the meta-analysis. Random-effects meta-analysis showed that patients with AD had significantly decreased baseline peripheral blood levels of BDNF compared with healthy control (HC) subjects (24 studies, Hedges' g=−0.339, 95% confidence interval (CI)=−0.572 to −0.106, P=0.004). MCI subjects showed a trend for decreased BDNF levels compared with HC subjects (14 studies, Hedges' g=−0.201, 95% CI=−0.413 to 0.010, P=0.062). No differences were found between AD and MCI subjects in BDNF levels (11 studies, Hedges' g=0.058, 95% CI=−0.120 to 0.236, P=0.522). Interestingly, the effective sizes and statistical significance improved after excluding studies with reported medication in patients (between AD and HC: 18 studies, Hedges' g=−0.492, P<0.001; between MCI and HC: 11 studies, Hedges' g=−0.339, P=0.003). These results strengthen the clinical evidence that AD or MCI is accompanied by reduced peripheral blood BDNF levels, supporting an association between the decreasing levels of BDNF and the progression of AD.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , . Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease. BioMed Res Int 2014; 2014: 175062.

  2. 2.

    , . Memory loss in Alzheimer's disease: implications for development of therapeutics. Expert Revi Neurother 2008; 8: 1879–1891.

  3. 3.

    , , , , , et al. Current and novel therapeutic molecules and targets in Alzheimer's disease. J Formos Med Assoc 2015; 115: 3–10.

  4. 4.

    , , , , , et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected]. Medicine 2014; 93: e150.

  5. 5.

    . 2015 Alzheimer's disease facts and figures. Alzheimer Dement 2015; 11: 332–384.

  6. 6.

    , . Galanin protects amyloid-beta-induced neurotoxicity on primary cultured hippocampal neurons of rats. J Alzheimer's Disease 2010; 20: 1143–1157.

  7. 7.

    , . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353–356.

  8. 8.

    . Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimer's Dis 2012; 2012: 369808.

  9. 9.

    , , . Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8: 663–672.

  10. 10.

    , . New perspectives on the role of tau in Alzheimer's disease. Implications for therapy. Biochem Pharmacol 2014; 88: 540–547.

  11. 11.

    , , . The neurotrophins and their role in Alzheimer's disease. Curr Neuropharmacol 2011; 9: 559–573.

  12. 12.

    , , , . Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies. Curr Alzheimer Res 2014; 11: 27–39.

  13. 13.

    , . Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008; 33: 73–83.

  14. 14.

    , , , . New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 2009; 29: 12764–12767.

  15. 15.

    . Brain-derived neurotrophic factor: three ligands, many actions. Trans Am Clin Climatol Assoc 2015; 126: 9–19.

  16. 16.

    , , , , , et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008; 40: 768–775.

  17. 17.

    , , , , , . Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 1997; 49: 71–81.

  18. 18.

    , , , , , et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 1999; 58: 729–739.

  19. 19.

    , , . A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J Neurochem 2002; 82: 1058–1064.

  20. 20.

    , , , , . Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res Mol Brain Res 2000; 76: 347–354.

  21. 21.

    , , , . Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 2005; 93: 1412–1421.

  22. 22.

    , , , , , . BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991; 7: 695–702.

  23. 23.

    , , , , , . Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci 2000; 18: 807–813.

  24. 24.

    , , , , , et al. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. Neuroscience 1999; 88: 1015–1032.

  25. 25.

    , , , , . Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553–1561.

  26. 26.

    , , , , . Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry 2014; 19: 750–751.

  27. 27.

    , , , , , et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry 2015; 20: 1108–1119.

  28. 28.

    , , , , , et al. Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry 2010; 11: 774–780.

  29. 29.

    , , , , , et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatric Res 2007; 41: 387–394.

  30. 30.

    , , , , , et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimer's Dis 2009; 16: 649–656.

  31. 31.

    , , , , , et al. Associations Between ApoEepsilon4 Carrier Status and Serum BDNF Levels—New Insights into the Molecular Mechanism of ApoEepsilon4 Actions in Alzheimer's Disease. Mol Neurobiol 2015; 51: 1271–1277.

  32. 32.

    , , , , , et al. Serum brain-derived neurotrophic factor levels in different neurological diseases. BioMed Res Int 2013; 2013: 901082.

  33. 33.

    , , , , , et al. Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. J Clin Psychiatry 2008; 69: 1104–1111.

  34. 34.

    , , , , . Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer's disease. J Alzheimer's Dis 2014; 42: 1347–1355.

  35. 35.

    , , , , , et al. Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res 2010; 7: 15–20.

  36. 36.

    , , , . Val66Met polymorphism and BDNF levels in Alzheimer's disease patients in North Indian population. Int J Neurosci 2013; 123: 409–416.

  37. 37.

    , , , , , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1–34.

  38. 38.

    , , , , , et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. J Neuroimmunol 2015; 283: 50–57.

  39. 39.

    , , , , , et al. Serum brain-derived neurotrophic factor is associated with cognitive function in healthy older adults. J Geriatr Psychiatry Neurol 2008; 21: 166–170.

  40. 40.

    , , , , . A randomised controlled trial investigating the effects of Mediterranean diet and aerobic exercise on cognition in cognitively healthy older people living independently within aged care facilities: the Lifestyle Intervention in Independent Living Aged Care (LIILAC) study protocol [ACTRN12614001133628]. Nutr J 2015; 14: 53.

  41. 41.

    , , , , , et al. Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease. Biochem Biophys Res Commun 2013; 430: 907–911.

  42. 42.

    , , , , , et al. BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol Learn Mem 2008; 90: 596–603.

  43. 43.

    , , , , , et al. The associations between serum brain-derived neurotrophic factor, potential confounders, and cognitive decline: a longitudinal study. PLoS ONE 2014; 9: e91339.

  44. 44.

    , , , , , et al. Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. JAMA Neurol 2014; 71: 55–61.

  45. 45.

    , , , , , et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010; 67: 71–79.

  46. 46.

    , , , , , et al. Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. Int J Neuropsychopharmacol 2011; 14: 399–404.

  47. 47.

    , , , , , et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PloS ONE 2013; 8: e61483.

  48. 48.

    , , , , , et al. Decreased neurotrophic support is associated with cognitive decline in non-demented subjects. J Alzheimer's Dis 2015; 46: 423–429.

  49. 49.

    , , , , , et al. Brain-derived neurotrophic factor levels in Alzheimer's disease. J Alzheimer's Dis 2009; 17: 337–341.

  50. 50.

    , , , , , et al. The stimulation of dendritic cells by amyloid beta 1-42 reduces BDNF production in Alzheimer's disease patients. Brain Behav Immun 2013; 32: 29–32.

  51. 51.

    , , , , , et al. Psychophysiological correlates of cognitive deficits in family caregivers of patients with Alzheimer Disease. Neuroscience 2015; 286: 371–382.

  52. 52.

    , , , , , et al. Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: a longitudinal study. J Psychiatr Res 2014; 49: 96–101.

  53. 53.

    , , , , , et al. Cognitive function in elderly marathon runners: cross-sectional data from the marathon trial (APSOEM). Wien Klin Wochenschr 2010; 122: 704–716.

  54. 54.

    , , , , , et al. Lack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory. Cogn Affect Behav Neurosci 2015; 15: 625–643.

  55. 55.

    , , , , , et al. Acute aerobic exercise increases brain-derived neurotrophic factor levels in elderly with Alzheimer's disease. J Alzheimer's Dis 2014; 39: 401–408.

  56. 56.

    , , , , , et al. The presence of depressive symptoms in comorbidity with Alzheimer's disease does not influence changes in serum brain-derived neurotrophic factor levels in older patients. Int J Geriatr Psychiatry 2014; 29: 439–440.

  57. 57.

    , , , , , et al. Increased plasma levels of BDNF and inflammatory markers in Alzheimer's disease. J Psychiatr Res 2014; 53: 166–172.

  58. 58.

    , , , , , et al. BDNF, TNFalpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment. J Alzheimer's Dis 2013; 37: 185–195.

  59. 59.

    , , , , , et al. Plasma BDNF levels associate with Pittsburgh compound B binding in the brain. Alzheimer's Dement 2015; 1: 187–193.

  60. 60.

    , , , , . Serum brain-derived neurotrophic factor, nerve growth factor and neurotrophin-3 levels in dementia. Acta Neurol Belgica 2012; 112: 255–260.

  61. 61.

    , , , , , et al. Decreased brain-derived neurotrophic factor (BDNF)- and beta-thromboglobulin (beta-TG)- blood levels in Alzheimer's disease. Thromb Haemost 2006; 96: 102–103.

  62. 62.

    , , , , , et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 2006; 113: 1217–1224.

  63. 63.

    , , , , , et al. Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. Psychiatry Invest 2009; 6: 299–305.

  64. 64.

    , , , , . Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2008; 258: 124–128.

  65. 65.

    , , , , , . Plasma BDNF levels are correlated with aggressiveness in patients with amnestic mild cognitive impairment or Alzheimer disease. J Neural Transm 2014; 121: 433–441.

  66. 66.

    , , , , , et al. Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr Alzheimer Res 2014; 11: 799–805.

  67. 67.

    , , , , , et al. Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement Geriatr Cogn Disord 2011; 31: 31–36.

  68. 68.

    , , , , , et al. Brain-derived neurotrophic factor plasma levels: relationship with dementia and diabetes in the elderly population. J Gerontol A, Biol Sci Med Sci 2015; 70: 294–302.

  69. 69.

    , , , , , et al. GSK3beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. Prog Neuro-psychopharmacol Biol Psychiatry 2014; 50: 83–93.

  70. 70.

    , , , , , et al. A large, cross-sectional observational study of serum BDNF, cognitive function, and mild cognitive impairment in the elderly. Front Aging Neurosci 2014; 6: 69.

  71. 71.

    , , , , , et al. Enhancing diagnostic accuracy of aMCI in the elderly: combination of olfactory test, pupillary response test, BDNF plasma level, and APOE genotype. Int J Alzheimer's Disease 2014; 2014: 912586.

  72. 72.

    , , , , , et al. Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer's disease in patients with the apolipoprotein E 4 genotype. Biomarkers 2015; 20: 84–88.

  73. 73.

    , , , , , et al. BDNF serum concentrations show no relationship with diagnostic group or medication status in neurodegenerative disease. Curr Alzheimer Res 2012; 9: 815–821.

  74. 74.

    , , , , . Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2006; 256: 402–406.

  75. 75.

    , , , , . Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. Mol Psychiatry 2016; (in press).

  76. 76.

    , , , . Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol 2011; 11: 41.

  77. 77.

    , , , , , . Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry 2015; 20: 440–446.

  78. 78.

    , , . Quantitative synthesis in systematic reviews. Ann Int Med 1997; 127: 820–826.

  79. 79.

    , , , . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

  80. 80.

    , . Assessing publication bias in meta-analysis. Nurs Res 2003; 52: 57–60.

  81. 81.

    , , , , , et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87: 728–734.

  82. 82.

    , , , , , . Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull 2007; 73: 143–149.

  83. 83.

    , , . Detection of brain-derived neurotrophic factor (BDNF) in rat blood and brain preparations using ELISA: pitfalls and solutions. J Neurosci Methods 2010; 187: 73–77.

  84. 84.

    , , , , , et al. Upregulation of blood proBDNF and its receptors in major depression. J Affect Disord 2013; 150: 776–784.

  85. 85.

    , , . Depression in dementia: epidemiology, mechanisms, and treatment. Curr Opin Psychiatry 2011; 24: 461–472.

  86. 86.

    , , . The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function. Med Sci Sports Exerc 2007; 39: 728–734.

  87. 87.

    , . Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101–112.

  88. 88.

    , , , , , et al. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 2013; 136(Pt 5): 1383–1398.

  89. 89.

    , , . ApoE4 and Abeta Oligomers reduce BDNF expression via HDAC nuclear translocation. J Neurosci 2015; 35: 7538–7551.

  90. 90.

    , , , . Epigenetic suppression of hippocampal BDNF mediates the memory deficiency induced by amyloid fibrils. Pharmacol Biochem Behav 2014; 126: 83–89.

  91. 91.

    , , , , , et al. Association between DNA Methylation of the BDNF Promoter Region and Clinical Presentation in Alzheimer's Disease. Dement Geriatr Cogn Disord Extra 2015; 5: 64–73.

  92. 92.

    , , , , , et al. miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol 2012; 72: 269–277.

  93. 93.

    , , , , , et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ 2005; 12: 1329–1343.

  94. 94.

    , , , , , et al. Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis 2008; 31: 316–326.

  95. 95.

    , , , . Brain-derived neurotrophic factor inhibits cell cycle reentry but not endoplasmic reticulum stress in cultured neurons following oxidative or excitotoxic stress. J Neurosci Res 2010; 88: 2263–2271.

  96. 96.

    , , , , , . Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 2011; 172: 398–405.

  97. 97.

    , , , , , et al. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci 2013; 33: 15596–15602.

  98. 98.

    , , , , , . Amyloid beta, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track? CNS Neurosci Ther 2013; 19: 549–555.

  99. 99.

    , , , , , . A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010; 68: 930–941.

  100. 100.

    , . Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev 2013; 2013: 316523.

  101. 101.

    , , , , . BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 2013; 14: 401–416.

  102. 102.

    , , . Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 2009; 66: 488–497.

  103. 103.

    , , . A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review. Neurosci Biobehav Rev 2015; 51: 15–30.

  104. 104.

    , , , , . Gender-related association of brain-derived neurotrophic factor gene 196A/G polymorphism with Alzheimer's disease—a meta-analysis including 6854 cases and 6868 controls. Int J Neurosci 2014; 124: 724–733.

  105. 105.

    , , , . Association of rs6265 and rs2030324 polymorphisms in brain-derived neurotrophic factor gene with Alzheimer's disease: a meta-analysis. PLoS ONE 2014; 9: e94961.

  106. 106.

    , , , , , et al. Association of and with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls. Exp Ther Med 2015; 9: 1831–1840.

  107. 107.

    Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998; 19: 109–116.

  108. 108.

    , , , , , . Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 2014; 19: 791–800.

  109. 109.

    . Mild cognitive impairment: structural, metabolical, and neurophysiological evidence of a Novel EEG Biomarker. Front Neurol 2015; 6: 152.

  110. 110.

    , , . Blood-based proteomic biomarkers of Alzheimer's disease pathology. Front Neurol 2015; 6: 236.

  111. 111.

    , , , , , et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359–1362.

  112. 112.

    , , , . Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS ONE 2012; 7: e29868.

  113. 113.

    , , , , , et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2011; 32: 539–540.

  114. 114.

    , , , , , . Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 2009; 1180: 56–67.

  115. 115.

    , , , , , et al. Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease. J Proteomics 2012; 75: 3617–3629.

  116. 116.

    , , , , , et al. Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry 2015; 20: 126–132.

  117. 117.

    , , , , , . Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies. Transl Psychiatry 2015; 5: e501.

  118. 118.

    , , , , , . Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. J Alzheimer's Dis 2015; 50: 249–260.

Download references

Acknowledgements

This research was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, USA, the Minzu University 985 Academic Team-building Fund (YLDX01013, 2015MDTD13C, 25C and 08C) and the 111 Project of China (B08044).

Author contributions

YC and X-YQ conceived and designed the study, X-YQ and CC collected the data. X-YQ, CC, NXC, T-TL, JY, YPL and YC analyzed and interpreted the data. YC wrote the manuscript with editing from NXC.

Author information

Author notes

    • X-Y Qin
    •  & C Cao

    These authors contributed equally to this work.

Affiliations

  1. Section on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China

    • X-Y Qin
    • , C Cao
    • , T-T Liu
    •  & J Yuan
  2. Section on Cellular Neurobiology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA

    • N X Cawley
    • , Y P Loh
    •  & Y Cheng

Authors

  1. Search for X-Y Qin in:

  2. Search for C Cao in:

  3. Search for N X Cawley in:

  4. Search for T-T Liu in:

  5. Search for J Yuan in:

  6. Search for Y P Loh in:

  7. Search for Y Cheng in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to Y Cheng.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/mp.2016.62

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)